CHAPTER 54 INTRA-ARTERIAL tPA IN ACUTE ISCHEMIC STROKE: THE PROACT II STUDY

Intra-arterial Prourokinase for Acute Ischemic Stroke. The PROACT II Study: A Randomized Controlled Trial

Furlan A, Higashida R, Wechsler L, et al. JAMA. 1999;282(21):2003–2011

BACKGROUND

The NINDS trial shows that intravenous tPA is beneficial when given to appropriate patients within 3 hours of stroke onset, but many acute stroke patients are present outside of this window. Prior to this study, PROACT I showed a mild benefit of intra-arterial prourokinase (IA tPA) if given up to 6 hours after stroke onset. It was thought, however, that a higher dose could increase this efficacy and required randomized study.

OBJECTIVES

To evaluate the efficacy of a higher dose of IA tPA than had previously studied in the PROACT I trial, as a therapy for acute middle cerebral artery (MCA) stroke patients who present within 6 hours of symptom onset.

METHODS

Open-label, randomized controlled trial with blinded follow-up conducted at 54 centers in the United States and Canada.

Participants

Related posts:

Oral vs. IV Rehydration Spontaneous Ureteral Stone Passage Heparinizing Unstable Angina Amiodarone in Ventricular Fibrillation Bicarbonate Therapy in DKA Point of Care Echo in Penetrating Cardiac Injury

Stay updated, free articles. Join our Telegram channel

Join